thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
The International History Review. 30 (4): 709–740. doi:10.1080/07075332.2008.10416646. ISSN 1949-6540. JSTOR 40213728. S2CID 153677447. Panzac, Daniel (1995). Histoire économique et sociale de l'Empire ottoman et de la Turquie (1326-1960). Peeters Publishers. ISBN 90-6831-799-7. Pappé, Ilan (2006). The Ethnic Cleansing of Palestine. Oneworld. ISBN 978-1-85168-555-4. Reilly, James A. (2016). The Ottoman Cities of Lebanon: Historical Legacy and Identity in the Modern Middle East. London: I. B. Tauris. ISBN 978-1-78672-036-8. Salibi, Kamal S. (January 1961). "The Buḥturids of the Garb. Mediaeval Lords of Beirut and of Southern Lebanon". Arabica. 8 (1): 74–97. doi:10.1163/157005861X00043. JSTOR 4054971. Salibi, K. (1965). "Fakhr al-Dīn". In Lewis, B.; Pellat, Ch. & Schacht, J. (eds.). The Encyclopaedia of Islam, Second Edition. Volume II: C–G. Leiden: E. J. Brill. pp. 749–751. OCLC 495469475. Salibi, K. (February 1968). "The muqaddams of Bšarrī: Maronite chieftains of the Northern Lebanon 1382–1621". Arabica. 15 (1): 63–86. doi:10.1163/157005868X00280. ISSN 0570-5398. JSTOR 4056124. Salibi, K. (2005). A House of Many Mansions: The History of Lebanon Reconsidered. London: I.B. Tauris. ISBN 978-1-86064-912-7. Salibi, Kamal Suleiman (2005b). The Druze: Realities & Perceptions. University of Michigan Press. ISBN 978-1-904850-06-9. Schilcher, L. Schatkowski (1981). "The Hauran Conflicts of the 1860s: A Chapter in the Rural History of Modern Syria". International Journal of Middle East Studies. 13 (2): 159–179. doi:10.1017/S0020743800055276. JSTOR 162818. S2CID 162263141.
== Data management == The FDA has collected a large amount of data through the decades. The OpenFDA project was created to enable easy access of the data for the public and was officially launched in June 2014.
Entry clones must be made using the supplied "Donor" vectors containing a Gateway cassette flanked by attP sites. The Gateway cassette contains a bacterial suicide gene (e.g. ccdB) that will allow for survival and selection of successfully recombined entry clones. A pair of attB sites are added to flank the DNA fragment of interest, and this will allow recombination with the attP sites when the BP clonase mix is added. Entry clones are produced, and the fragment of interest is flanked by attL sites. The destination vector also comes with a Gateway cassette, but is instead flanked by a pair of attR sites. Mixing this destination plasmid with the entry clones and the LR clonase mix will allow for recombination to occur between the attR and attL sites. A destination clone is produced, with the fragment of interest successfully inserted. The lethal gene is inserted into the original vector, and bacteria transformed with this plasmid will die. The desired vector can thus be easily selected. The earliest iterations of the Gateway cloning method only allowed for only one entry clone to be used for each destination clone produced. However, further research revealed that four more orthogonal att sequences could be generated, allowing for the assembly of up to four different DNA fragments, and this process is now known as the Multisite Gateway technology. Besides Gateway cloning, non-commercial methods using other integrases have also been developed.
Greater bulldog bats honk when on a collision course with each other. Bats also communicate by other means. Male little yellow-shouldered bats (Sturnira lilium) use a spicy odour secreted from their shoulder glands during the breeding season, retained and spread by specialised hairs. These hairs exist in other species, which are noticeable as collars around the necks in some Old World megabat males. Male greater sac-winged bats (Saccopteryx bilineata) have sacs in their wings in which they mix body secretions like saliva and urine to create a perfume that they sprinkle on roost sites, a behaviour known as "salting". The bats may sing while salting.
== Contraindications == Gabapentin should be used carefully and at lower doses in people with kidney problems due to possible accumulation and toxicity. It is unclear if it is safe during pregnancy or breastfeeding.
Sources: en.wikipedia.org
=== Pasteurized donkey milk === Donkey milk is pasteurized in a closed circuit of pasteurization and bottling (aseptic) at least 72 °C for 15 seconds or equivalent times and temperatures. In the case of pasteurization in discontinuous systems, the temperature must be higher depending on the method used and the type of plant and destination.
President Wee Kim Wee accepted her plea for clemency in 1992 and her death sentence was commuted to life imprisonment; her two accomplices, however, were executed in 1992. While serving her life sentence, she was diagnosed with cervical cancer in 1993 and had at most a year to live. She appealed to President Ong Teng Cheong for clemency so that she could be released in order to spend the final moments of her life with her family. The president accepted the petition, and she was released on 16 February 1995 and eventually died on 30 March that year. 1992: Koh Swee Beng, a Singaporean who killed a man who assaulted his foster father in 1988. He was convicted of murder and sentenced to hang in 1990. He lost his appeal against his death sentence in 1991 but was eventually granted clemency by President Wee Kim Wee on 13 May 1992 (two days before he was scheduled to be executed) and had his sentence commuted to life imprisonment. He was released from prison in September 2005 for good behaviour after serving at least two-thirds of his life sentence. 1998: Mathavakannan Kalimuthu, a Singaporean convicted of murder and sentenced to hang in 1996 along with his two friends. After losing their appeals in 1997, the three of them petitioned to President Ong Teng Cheong for clemency in 1998. The president accepted only Mathavakannan's plea so his sentence was commuted to life imprisonment; the other two had their pleas rejected and were subsequently executed. Mathavakannan was eventually released in 2012 after spending about 16 years in prison.
Arizona Medical Training Institute (AMTI) is a private, vocational healthcare institute located in Mesa, Arizona. They provide entry-level medical training for students seeking careers in nursing, clinical laboratory science and the assisted living career fields.
== Mechanism of action == Difenoxin has a high peripheral/central actions ratio, working primarily on various opioid receptors in the intestines. Although it is capable of producing significant central effects at high doses, doses within the normal therapeutic range generally do not notably impair cognition or proprioception, resulting in therapeutic activity roughly equatable to that of loperamide (Imodium). Increased dosages result in more prominent central opioid effects (and anticholingeric effects when the formulation also contains a tropane alkaloid). It therefore offers limited advantages over more potent anti-diarrheal opioid options (ex. morphine) when treating intractable cases of diarrhea which fail to respond to normal or moderately increased difenoxin doses, and may in fact be harmful in such circumstances if the formulation used also contains atropine or hyoscyamine.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.